



Please type a plus sign (+) inside this box →

PTO/SB/08A (10-96)

Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 2

Complete If Known

Application Number	10/677,683
Filing Date	October 2, 2003
First Named Inventor	BORCHERDING et al.
Group Art Unit	1624
Examiner Name	BERCH, Mark L.

Sheet 1 of 2

11. *What is the name of the person who is the author of the book?*

Attorney Docket Number USA3960 US CNT

U.S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Office ³	Number ⁴	Kind Code ⁵ (if known)			
AB	•	EP	0545413			07-12-2000	
AB	•	WO	WO 00/44750			08-03-2000	
AB	•	WO	WO 94/17090			08-04-1994	
AB	•	WO	WO 96/02543			02-01-1996	
AB	•	WO	WO 97/16452			05-09-1997	
		WO	WO 97/20,842			06-12-1997	
AB	•	WO	WO 98/05335			02-12-1998	
AB	•	WO	WO 99/07705			02-18-1999	

**Examiner
Signature**

Mark B.

Date
Considered

3/22/06

***EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the Indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:** Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box →

PTO/SB/08B (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

2

of

2

Complete If Known

Application Number	10/677,683
Filing Date	October 2, 2003
First Named Inventor	BORCHERDING et al.
Group Art Unit	1624
Examiner Name	BERCH, Mark L.
Attorney Docket Number	USA3960 US CNT

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
M		*KATH John C, Patent Focus: Inhibitors of Tumour Cell Growth, J.C., Oncologic, Endocrine & Metabolic, Exp. Opin. Ther. Patents (2000), 10(6):803:818	
MM		*MYERS Michael R et al., Inhibitors of Tyrosine Kinases Involved in Inflammation and Autoimmune Disease, Current Pharmaceuticals Design, 1997, Vol. 3, No. 5, pages 473-502	
MM		*PARK David S et al., G1/S Cell Cycle Blockers and Inhibitors of Cyclin-Dependent Kinases Suppress Camptothecin-Induced Neuronal Apoptosis, J. of Neuroscience, 17(4):1256-1270 (1997)	
MB		*PARK David S et al., Inhibitors of Cyclin-Dependent Kinases Promote Survival of Post-mitotic Neuronally Differentiated PC12 Cells and Sympathetic Neurons, J. of Biological Chemistry, Vol. 271, No. 14:8161-8169 (1996)	
MP		*ROSANIA Gustavo R et al., Targeting Hyperproliferative Disorders with Cyclin Dependent Kinase Inhibitors, Publication Exp. Opin. Ther. Patents (2000) 10(2):215-230	

Examiner
Signature

Date
Considered

3/22/06

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.